Executive Summary
India's IPO activity remains robust with Coal India Limited filing the RHP for its subsidiary CMPDIL's IPO on March 12, 2026, signaling potential value unlock via OFS of 107.1M shares amid neutral sentiment. Arco Leasing Ltd saw a public announcement for an open offer, labeled as an IPO listing event, though lacking details on terms or size, highlighting acquisition-related activity in the technology/leasing space. Gujarat Kidney And Super Speciality Limited (GKS), post its December 30, 2025 listing, reported mixed H1 FY26 results with revenue up 12.9% YoY to ₹21.09 Cr but down 15.8% QoQ in Q2, PAT up 10.1% YoY to ₹6.20 Cr yet down 41% QoQ, and negative operating cash flow of ₹8.23 Cr due to working capital expansion. Overarching themes include fresh IPO filings in mining/energy subsidiaries and post-IPO cash burn in healthcare, with no insider activity or forward-looking guidance disclosed across filings. Portfolio-level trends show YoY revenue growth in recent listers but QoQ weakness and liquidity strains, implying selective opportunities in pre-IPO unlocks versus post-listing stabilization plays. Critical implication: Monitor CMPDIL IPO timeline for CIL shareholder value and GKS cash flow recovery for healthcare IPO alpha.
Tracking the trend? Catch up on the prior India IPO SEBI DRHP Activity Filings digest from March 12, 2026.
Investment Signals(11)
- Coal India (CMPDIL IPO)(BULLISH)▲
RHP filed March 12, 2026 for OFS of up to 107.1M shares, potential value unlock for CIL shareholders via subsidiary listing
- CMPDIL(BULLISH)▲
Wholly-owned subsidiary IPO disclosure under Reg 30 SEBI LODR, neutral sentiment with high materiality 9/10, first major coal planning IPO in 2026
- Gujarat Kidney (GKS)(BULLISH)▲
H1 FY26 revenue +12.9% YoY to ₹21.09 Cr post-IPO listing Dec 30, 2025, outperforming prior H1 ₹18.67 Cr
- GKS(BULLISH)▲
PAT +10.1% YoY to ₹6.20 Cr for H1 FY26, EPS ₹1.22 basic, supporting post-IPO expansion with total assets +36.4% to ₹66.94 Cr
- GKS(BULLISH)▲
Equity capital expanded to ₹11.37 Cr post-IPO, funding asset growth from ₹49.07 Cr as of Mar 31, 2025
- Arco Leasing(BULLISH)▲
Public announcement for open offer submitted March 13, 2026 under SEBI regs, signaling potential control change or consolidation
- GKS(NEUTRAL)▲
Q2 revenue +2.5% YoY to ₹9.64 Cr despite QoQ -15.8% from ₹11.45 Cr, resilient topline in healthcare IPO cohort
- GKS(BEARISH)▲
PAT down 41% QoQ to ₹2.30 Cr from ₹3.90 Cr but stable YoY, mixed post-IPO profitability trend
- GKS(BEARISH)▲
Operating cash flow negative ₹8.23 Cr H1 FY26 vs +₹2.94 Cr H1 FY25, driven by working capital for expansion
- Arco Leasing(BEARISH)▲
No quantitative metrics or offer details disclosed, low materiality 3/10 vs peers' detailed filings
- Portfolio (IPO Monitor)(NEUTRAL)▲
1/3 filings show YoY revenue growth (GKS +12.9%), but QoQ declines in post-lister, avg IPO materiality 6.7/10
Risk Flags(8)
- GKS/Cash Flow[HIGH RISK]▼
Net operating cash negative ₹8.23 Cr H1 FY26 (vs +₹2.94 Cr H1 FY25), due to working capital changes post-IPO expansion
- GKS/Quarterly Trends[MEDIUM RISK]▼
Q2 revenue -15.8% QoQ to ₹9.64 Cr from ₹11.45 Cr, PAT -41% QoQ to ₹2.30 Cr, signaling post-listing slowdown
- GKS/Reporting[LOW RISK]▼
Results submitted with delay due to technical issues for Q2/H1 FY26, despite prior Dec 2025 compliance
- Arco Leasing/Disclosure[MEDIUM RISK]▼
No details on open offer acquirer, size, terms, or shareholding changes; risk level low but opacity high
- Arco Leasing/Regulatory[MEDIUM RISK]▼
Open offer under SEBI Regs 3(1),4,13(1),14,15(1) lacks financials or listing performance data
- CMPDIL IPO/Market Conditions[LOW RISK]▼
OFS of 107.1M shares subject to approvals and market conditions, potential delay risk in volatile 2026 IPO market
- Portfolio/Trends[MEDIUM RISK]▼
2/3 filings neutral/mixed sentiment, with GKS QoQ declines vs YoY gains, post-IPO cash burn outlier
- GKS/Liquidity[HIGH RISK]▼
Negative cash flow amid asset growth to ₹66.94 Cr, potential strain if working capital issues persist
Opportunities(8)
- CMPDIL/Catalyst(OPPORTUNITY)◆
RHP filed Mar 12, 2026 for IPO, track for SEBI approval and pricing; CIL OFS could unlock subsidiary value (ISIN CIL INE522F01014)
- Coal India/Shareholder Value(OPPORTUNITY)◆
Parent selling up to 107.1M CMPDIL shares via OFS, potential re-rating for CIL scrip 533278 post-listing
- GKS/Post-IPO Growth(OPPORTUNITY)◆
Assets +36.4% to ₹66.94 Cr, equity + post Dec 30, 2025 listing, YoY revenue/PAT gains position for healthcare expansion alpha
- GKS/Turnaround(OPPORTUNITY)◆
H1 PAT +10.1% YoY to ₹6.20 Cr despite cash burn, EPS ₹1.22; monitor Q3 for working capital normalization
- Arco Leasing/Open Offer(OPPORTUNITY)◆
Potential acquisition play via open offer announced Mar 13, 2026; low-risk entry if terms reveal premium
- GKS/Relative Performance(OPPORTUNITY)◆
Q2 revenue +2.5% YoY outperforms QoQ weakness, undervalued post-IPO healthcare play vs sector cash-rich peers
- Portfolio/IPO Pipeline(OPPORTUNITY)◆
2 new events (CMPDIL filing, Arco offer) since last brief, early positioning in 2026 mining/tech IPOs
- GKS/Expansion(OPPORTUNITY)◆
Total assets growth from ₹49.07 Cr to ₹66.94 Cr signals capacity build post-listing, alpha in super-speciality kidney segment
Sector Themes(5)
- IPO Filing Momentum◆
1/3 filings (CMPDIL) introduce fresh RHP in mining/energy subsidiaries, high materiality 9/10, implying parent monetization trend [IMPLICATION: Bullish for listed parents like CIL]
- Post-IPO Cash Dynamics◆
GKS shows H1 FY26 op cash -₹8.23 Cr vs +prior year amid +36% assets, common in expansion-phase healthcare IPOs [IMPLICATION: Watch liquidity in new listers]
- Neutral Sentiment Dominance◆
2/3 filings neutral (CMPDIL, Arco), mixed in GKS; avg materiality 6.7/10 reflects steady but non-explosive IPO flow [IMPLICATION: Selective picks over broad exposure]
- YoY vs QoQ Divergence◆
GKS revenue +12.9% YoY H1 but -15.8% Q2 QoQ, PAT +10.1% YoY/-41% QoQ; post-IPO normalization pattern [IMPLICATION: Favor YoY growers with QoQ inflection]
- Disclosure Gaps in Offers◆
Arco open offer lacks metrics (3/10 materiality) vs detailed GKS results, trend in acquisition-linked 'IPO listings' [IMPLICATION: Demand more data before trading]
Watch List(7)
- CMPDIL/SEBI Approval👁
Track RHP progress post Mar 12, 2026 filing for IPO timeline, pricing, and OFS size; disclosure ref CIL:XI(D):4157/4156:2026:34587 [Mar-Apr 2026]
- Coal India/CIL Stock👁
Monitor reaction to CMPDIL IPO news on scrip 533278 (ISIN INE522F01014) for value unlock catalysts [Ongoing]
- Arco Leasing/Open Offer👁
Watch for detailed PAUP or terms on acquirer, size, pricing under SEBI regs; BSE 511038 [Next 7-14 days]
- GKS/Q3 FY26 Results👁
Monitor for cash flow recovery from H1 -₹8.23 Cr negative, revenue QoQ rebound post -15.8% Q2 [May-Jun 2026]
- GKS/Working Capital👁
Track operating cash trends vs H1 FY25 +₹2.94 Cr, potential inflection in post-IPO expansion [Q3 FY26]
- Portfolio/IPO Cohort👁
New filings (2/3 since last brief) signal rising activity; watch aggregate listing performance vs GKS mixed results [Mar 2026 onward]
- Arco Leasing/Shareholding👁
Pending open offer details on changes, risk if no updates; compare to GKS post-listing equity ₹11.37 Cr [Immediate]
Filing Analyses(3)
13-03-2026
Coal India Limited disclosed the filing of the Red Herring Prospectus (RHP) dated March 12, 2026, for its wholly owned subsidiary Central Mine Planning and Design Institute Limited (CMPDIL) with SEBI, BSE, and NSE, pertaining to CMPDIL's proposed initial public offering. The IPO comprises an offer for sale of up to 107,100,000 equity shares by Coal India Limited, subject to applicable approvals, market conditions, and other considerations. This disclosure complies with Regulation 30 of SEBI (LODR) Regulations, 2015.
- ·RHP filed with SEBI, BSE, and NSE on March 12, 2026
- ·Disclosure reference: CIL:XI(D):4157/4156:2026:34587 dated March 13, 2026
- ·CIL ISIN: INE522F01014; Scrip Code: 533278
13-03-2026
Arco Leasing Ltd (BSE: 511038), a technology sector company, has had a Public Announcement for an Open Offer submitted to BSE by JJ IPO Advisors Pvt Ltd, the Manager to the Offer, under SEBI Regulations 3(1), 4 read with 13(1), 14, and 15(1). The filing is dated March 13, 2026, and labeled as an IPO Listing event, but contains no details on IPO stages, pricing, listing performance, financials, or offer specifics. No quantitative metrics, shareholding changes, or scheduled events are disclosed.
13-03-2026
Gujarat Kidney And Super Speciality Limited reported standalone unaudited financial results for Q2 and H1 FY26 ended September 30, 2025, with revenue from operations at ₹9.64 Cr for Q2 (up 2.5% YoY from ₹9.41 Cr but down 15.8% QoQ from ₹11.45 Cr) and ₹21.09 Cr for H1 (up 12.9% YoY from ₹18.67 Cr). PAT stood at ₹2.30 Cr for Q2 (down 41% QoQ from ₹3.90 Cr but up slightly YoY) and ₹6.20 Cr for H1 (up 10.1% YoY from ₹5.63 Cr), while operating cash flow was negative at ₹8.23 Cr due to working capital changes. Total assets grew to ₹66.94 Cr from ₹49.07 Cr as at March 31, 2025, reflecting post-IPO expansion with equity capital at ₹11.37 Cr.
- ·Company listed on BSE/NSE on December 30, 2025; results submitted with delay due to technical issues but prior upload for Dec 2025 quarter complied.
- ·Net cash from operating activities: negative ₹8.23 Cr for H1 FY26 vs positive ₹2.94 Cr H1 FY25.
- ·EPS basic Q2 FY26: ₹0.45 (diluted same); H1 FY26: ₹1.22.
- ·Single reportable segment: Trading of Pharma Goods.
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 3 filings
🇮🇳 More from India
View all →March 26, 2026
India Pre-Market Regulatory Roundup — March 26, 2026
India Pre-Market Regulatory Roundup
March 26, 2026
India Quarterly Results BSE NSE Announcements — March 26, 2026
India Quarterly Results BSE NSE Announcements
March 26, 2026
India Upcoming Corporate Actions BSE NSE — March 26, 2026
India Upcoming Corporate Actions BSE NSE
March 26, 2026
India MCA Insolvency Liquidation Filings — March 26, 2026
India MCA Insolvency Liquidation Filings